rofecoxib has been researched along with Atherogenesis in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " At this time, celecoxib is the only available COX-2-specific inhibitor for treatment of pain and inflammation." | 3.85 | COX-2-dependent and independent effects of COX-2 inhibitors and NSAIDs on proatherogenic changes in human monocytes/macrophages. ( Carsons, SE; De Leon, J; Gomolin, IH; Kasselman, LJ; Littlefield, MJ; Reiss, AB; Voloshyna, I, 2017) |
| "Rofecoxib was also found to promote the non-enzymatic formation of isoprostanes from biological lipids, which act as important mediators of inflammation in the atherosclerotic plaque." | 2.44 | A biological rationale for the cardiotoxic effects of rofecoxib: comparative analysis with other COX-2 selective agents and NSAids. ( Day, CA; Jacob, RF; Mason, RP; Walter, MF, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (77.78) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Voloshyna, I | 1 |
| Kasselman, LJ | 1 |
| Carsons, SE | 1 |
| Littlefield, MJ | 1 |
| Gomolin, IH | 1 |
| De Leon, J | 1 |
| Reiss, AB | 1 |
| Marzoll, A | 1 |
| Nagy, N | 2 |
| Wördehoff, L | 1 |
| Dai, G | 1 |
| Fries, S | 2 |
| Lindner, V | 1 |
| Grosser, T | 2 |
| Fischer, JW | 1 |
| Kaber, G | 1 |
| Kaiser, B | 1 |
| Baumgärtel-Allekotte, D | 1 |
| Rauch, B | 1 |
| Nossmann, S | 1 |
| Heim, Kh | 1 |
| Weber, A | 1 |
| Fischer, J | 1 |
| Schrör, K | 2 |
| Price, TS | 1 |
| Lawson, JA | 1 |
| Kapoor, S | 1 |
| DeMarco, S | 1 |
| Pletcher, MT | 1 |
| Wiltshire, T | 1 |
| FitzGerald, GA | 1 |
| Steffel, J | 1 |
| Akhmedov, A | 1 |
| Fähndrich, C | 1 |
| Ruschitzka, F | 1 |
| Lüscher, TF | 1 |
| Tanner, FC | 1 |
| Mason, RP | 1 |
| Walter, MF | 1 |
| Day, CA | 1 |
| Jacob, RF | 1 |
| Weber, AA | 1 |
| Heim, HK | 1 |
| Schumacher, M | 1 |
| Hohlfeld, T | 1 |
| Martínez-González, J | 1 |
| Badimon, L | 1 |
| Vinsonneau, U | 1 |
| Brondex, A | 1 |
| Mansourati, J | 1 |
| Saraux, A | 1 |
| Cornily, JC | 1 |
| Arlès, F | 1 |
| Godon, P | 1 |
| Quiniou, G | 1 |
3 reviews available for rofecoxib and Atherogenesis
| Article | Year |
|---|---|
A biological rationale for the cardiotoxic effects of rofecoxib: comparative analysis with other COX-2 selective agents and NSAids.
Topics: Atherosclerosis; Cell Membrane; Cyclooxygenase 2 Inhibitors; Humans; Lactones; Lipid Peroxidation; L | 2007 |
Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks.
Topics: Atherosclerosis; Cardiovascular Diseases; Consumer Product Safety; Cyclooxygenase 2; Cyclooxygenase | 2007 |
Cardiovascular disease in patients with spondyloarthropathies.
Topics: Antirheumatic Agents; Atherosclerosis; Atrioventricular Block; Cardiovascular Diseases; Comorbidity; | 2008 |
2 trials available for rofecoxib and Atherogenesis
| Article | Year |
|---|---|
Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2006 |
Effects of selective cyclooxygenase isoform inhibition on systemic prostacyclin synthesis and on platelet function at rest and after exercise in healthy volunteers.
Topics: Adenosine Diphosphate; Adult; Aspirin; Atherosclerosis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxy | 2007 |
4 other studies available for rofecoxib and Atherogenesis
| Article | Year |
|---|---|
COX-2-dependent and independent effects of COX-2 inhibitors and NSAIDs on proatherogenic changes in human monocytes/macrophages.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Biological Transport; Celecoxib; Cell Adhe | 2017 |
Cyclooxygenase inhibitors repress vascular hyaluronan-synthesis in murine atherosclerosis and neointimal thickening.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Carotid Arteries; Cyclooxygenase Inhibitors; Disease Mo | 2009 |
Antagonism of the antithrombotic and anti-atherosclerotic actions of aspirin by rofecoxib in the cholesterol-fed rabbit.
Topics: Animal Feed; Animals; Aorta; Aspirin; Atherosclerosis; Cholesterol; Cyclooxygenase 2; Cyclooxygenase | 2011 |
Differential effect of celecoxib on tissue factor expression in human endothelial and vascular smooth muscle cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Celecoxib; Cell Line; Endothelium, Vascula | 2006 |